http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
GOUDAH, A.,ABO EL-SOOUD, K.,SHIM, J.-H.,SHIN, H.-C.,ABD EL-ATY, A. M. Blackwell Publishing Ltd 2008 JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTIC Vol.31 No.5
<P>The target of the present study was to investigate the plasma disposition kinetics of levofloxacin in stallions (<I>n</I> = 6) following a single intravenous (i.v.) bolus or intramuscular (i.m.) injection at a dose rate of 4 mg/kg bwt, using a two-phase crossover design with 15 days as an interval period. Plasma samples were collected at appropriate times during a 48-h administration interval, and were analyzed using a microbiological assay method. The plasma levofloxacin disposition was best fitted to a two-compartment open model after i.v. dosing. The half-lives of distribution and elimination were 0.21 ± 0.13 and 2.58 ± 0.51 h, respectively. The volume of distribution at steady-state was 0.81 ± 0.26 L/kg, the total body clearance (<I>Cl</I><SUB>tot</SUB>) was 0.21 ± 0.18 L/h/kg, and the areas under the concentration–time curves (<I>AUC</I>s) were 18.79 ± 4.57 &mgr;g.h/mL. Following i.m. administration, the mean <I>t</I><SUB>1/2el</SUB> and <I>AUC</I> values were 2.94 ± 0.78 h and 17.21 ± 4.36 &mgr;g.h/mL. The bioavailability was high (91.76% ± 12.68%), with a peak plasma mean concentration (<I>C</I><SUB>max</SUB>) of 2.85 ± 0.89 &mgr;g/mL attained at 1.56 ± 0.71 h (<I>T</I><SUB>max</SUB>). The <I>in vitro</I> protein binding percentage was 27.84%. Calculation of efficacy predictors showed that levofloxacin might have a good therapeutic profile against Gram-negative and Gram-positive bacteria, with an <I>MIC</I> ≤ 0.1 &mgr;g/mL.</P>
Embryotoxic and Teratogenic Effects of Tartrazine in Rats
Hashem, Mohamed Mohammed,Abd-Elhakim, Yasmina Mohammed,Abo-EL-Sooud, Khaled,Eleiwa, Mona M.E. Korean Society of ToxicologyKorea Environmental Mu 2019 Toxicological Research Vol.35 No.1
Tartrazine (TAZ) is one of the most commonly used artificial dyes for foods and drugs. We determined the effect of TAZ on fetal development by examining morphological, visceral, and skeletal malformations in rat fetuses following daily oral administration of TAZ to pregnant Wistar rats at the 6th-15th day of gestation. TAZ at 0.45 and 4.5 mg/kg induced 6.0 and 7.1% fetal resorptions, as well as 10.0 and 10.5% fetal mortality, respectively. Fetal body weight and length were significantly lower in the groups treated with TAZ at 0.45 ($3.97{\pm}0.21g$ and $27.3{\pm}0.54mm$, respectively) and 4.5 mg/kg ($3.48{\pm}0.15g$ and $23.22{\pm}1.02mm$, respectively) than in the control group ($4.0{\pm}0.15g$ and $30.01{\pm}0.42mm$, respectively). TAZ at 0.45 and 4.5 mg/kg induced hepatic damage (20 and 33.3%, respectively), dark brown pigmentation due to hemosiderin in the splenic parenchyma (16.7 and 21.7%, respectively), as well as destructed and necrotic renal tubules (16.7 and 26.7%, respectively) in the fetuses. Moreover, TAZ at 0.45 and 4.5 mg/kg caused one or more missing coccygeal vertebrae (20 and 40%, respectively), missing sternebrae (6 and 10%, respectively), missing hind limbs (24 and 4%, respectively), and irregular ribs (16 and 20, respectively) in the fetuses. We concluded that TAZ has embryotoxic and teratogenic potentials in rats.
Embryotoxic and Teratogenic Effects of Tartrazine in Rats
Mohamed Mohammed Hashem,Yasmina Mohammed Abd-Elhakim,Khaled Abo-EL-Sooud,Mona M. E. Eleiwa 한국독성학회 2019 Toxicological Research Vol.35 No.1
Tartrazine (TAZ) is one of the most commonly used artificial dyes for foods and drugs. We determined the effect of TAZ on fetal development by examining morphological, visceral, and skeletal malformations in rat fetuses following daily oral administration of TAZ to pregnant Wistar rats at the 6th-15th day of gestation. TAZ at 0.45 and 4.5 mg/kg induced 6.0 and 7.1% fetal resorptions, as well as 10.0 and 10.5% fetal mortality, respectively. Fetal body weight and length were significantly lower in the groups treated with TAZ at 0.45 (3.97 ± 0.21 g and 27.3 ± 0.54 mm, respectively) and 4.5 mg/kg (3.48 ± 0.15 g and 23.22 ± 1.02 mm, respectively) than in the control group (4.0 ± 0.15 g and 30.01 ± 0.42 mm, respectively). TAZ at 0.45 and 4.5 mg/kg induced hepatic damage (20 and 33.3%, respectively), dark brown pigmentation due to hemosiderin in the splenic parenchyma (16.7 and 21.7%, respectively), as well as destructed and necrotic renal tubules (16.7 and 26.7%, respectively) in the fetuses. Moreover, TAZ at 0.45 and 4.5 mg/kg caused one or more missing coccygeal vertebrae (20 and 40%, respectively), missing sternebrae (6 and 10%, respectively), missing hind limbs (24 and 4%, espectively), and irregular ribs (16 and 20, respectively) in the fetuses. We concluded that TAZ has embryotoxic and teratogenic potentials in rats.